Beyond Steroids: What Veterinarians Should Know About Stem Cell Therapy for Feline IBD

Feline inflammatory bowel disease (IBD) is often a lifelong condition requiring sustained medical management. For many clinicians, prednisolone remains the cornerstone of therapy, yet prolonged corticosteroid use is not without drawbacks. Daily administration demands significant owner compliance, adverse effects remain a concern, and some patients continue to experience inadequate control of gastrointestinal signs despite treatment¹. 

These clinical realities have prompted growing interest in regenerative medicine approaches, particularly mesenchymal stem cell (MSC) therapy. Recent research evaluating adipose-derived feline MSCs (fMSCs) provides important insights into how stem cell therapy may fit into future feline IBD management. 

Building on Earlier Research 

An earlier proof-of-concept study demonstrated that freshly cultured allogeneic adipose-derived MSCs could be administered safely to cats with chronic enteropathy². However, that pilot study did not definitively differentiate inflammatory bowel disease from alimentary lymphoma, leaving uncertainty regarding the underlying pathology of enrolled cases. 

The newer investigation addressed this limitation by focusing specifically on cats with histologically confirmed IBD. This distinction is clinically important because therapeutic response may differ substantially depending on the underlying disease process. 

How MSCs May Influence Intestinal Inflammation 

MSCs are increasingly studied for immune-mediated disorders because of their ability to modulate inflammatory pathways rather than simply suppress immune activity broadly. These cells appear capable of homing toward inflamed tissues and producing immunomodulatory molecules that alter the behavior of inflammatory and immune cells¹. 

This mechanism may explain why MSC therapy has shown promise across multiple veterinary conditions. Beyond gastrointestinal disease, feline MSC therapy has also been explored in chronic gingivostomatitis and feline asthma^3,4. In cats with severe gingivostomatitis, some patients even achieved complete remission following intravenous administration of adipose-derived stem cells³. 

Lessons from Canine and Human IBD Research 

Much of the optimism surrounding MSC therapy in feline IBD originates from both canine and human medicine. 

In canine studies, intravenous administration of adipose-derived allogeneic MSCs resulted in significant improvement in clinical disease activity indices, serum albumin concentrations, and cobalamin levels. Histopathologic and endoscopic intestinal scores also improved following treatment¹. 

Another canine study evaluated dogs that either had not received previous therapy or had responded poorly to prednisolone. Following MSC infusion, all dogs receiving prednisone were successfully weaned from the medication over the course of the study⁵. 

Human medicine has reported similarly encouraging findings. Patients with refractory Crohn’s disease and ulcerative colitis experienced reductions in clinical activity scores after MSC treatment, and several patients were able to taper corticosteroid therapy successfully¹. 

What the Feline Study Demonstrated¹ 

In the feline study, cats receiving fMSC therapy underwent two intravenous infusions administered two weeks apart. The treatment was well tolerated, with no adverse reactions observed after either infusion. 

Clinically, the stem cell group achieved outcomes comparable to cats receiving prednisolone. Over the six-month study period, FCEAI scores improved significantly within the MSC-treated cats, while fecal scores also showed improvement trends. 

An especially relevant practical point for veterinarians is that meaningful clinical response occurred without the need for continuous daily immunosuppressive medication. For owners who struggle with chronic oral drug administration, this could represent a major advantage. 

Important Considerations for Clinical Practice 

Although the findings are promising, MSC therapy is still evolving and several unanswered questions remain. 

Veterinarians should recognize that stem cell protocols vary considerably between studies. Factors such as: 

• Donor selection  

• Cell culture conditions  

• Infusion frequency  

• Cell dose  

• Route of administration  

may all influence therapeutic success^1,6. Therefore, outcomes observed with one protocol cannot automatically be generalized to all MSC products or treatment approaches. 

Another important consideration is diagnostic accuracy. Differentiating IBD from small-cell alimentary lymphoma remains difficult despite histopathology and PARR analysis. The possibility of occult lymphoma remains an important limitation when interpreting studies involving feline chronic enteropathy. 

Looking Ahead 

The long-term implications of MSC therapy in feline patients remain largely unknown. Questions surrounding durability of remission, repeat treatment protocols, and potential effects in cats predisposed to alimentary lymphoma require further investigation. 

Nevertheless, the current evidence suggests that MSC therapy may become an important adjunct, or potentially an alternative, to corticosteroid-based management in selected feline IBD patients. 

For veterinarians managing chronic gastrointestinal disease, regenerative medicine is no longer a theoretical concept. It is increasingly becoming a realistic therapeutic consideration that may eventually reshape how feline IBD is approached in clinical practice. 

Reference 

1. Webb TL, Webb CB. Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease. Journal of feline medicine and surgery. 2022 Aug;24(8):e244-50. https://journals.sagepub.com/doi/pdf/10.1177/1098612X221104053 

2. Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study. Journal of feline medicine and surgery. 2015 Oct;17(10):901-8. https://journals.sagepub.com/doi/pdf/10.1177/1098612X14561105 

3. Arzi B, Clark KC, Sundaram A, Spriet M, Verstraete FJ, Walker NJ, Loscar MR, Fazel N, Murphy WJ, Vapniarsky N, Borjesson DL. Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory feline chronic gingivostomatitis. Stem cells translational medicine. 2017 Aug 1;6(8):1710-22. https://academic.oup.com/stcltm/article-pdf/6/8/1710/42633247/stcltm_6_8_1710.pdf 

4. Trzil JE, Masseau I, Webb TL, Chang CH, Dodam JR, Liu H, Quimby JM, Dow SW, Reinero CR. Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study. Journal of Feline Medicine and Surgery. 2016 Dec;18(12):981-90. https://journals.sagepub.com/doi/pdf/10.1177/1098612X15604351 

5. Cristóbal JI, Duque FJ, Usón-Casaús JM, Ruiz P, Nieto EL, Pérez-Merino EM. Effects of allogeneic mesenchymal stem cell transplantation in dogs with inflammatory bowel disease treated with and without corticosteroids. Animals. 2021 Jul 10;11(7):2061. https://www.mdpi.com/2076-2615/11/7/2061 

6. Zhang X, Wang S, Ding X, Guo J, Tian Z. Potential methods for improving the efficacy of mesenchymal stem cells in the treatment of inflammatory bowel diseases. Scandinavian journal of immunology. 2020 Sep;92(3):e12897. https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12897